The city of Houston, Texas, currently has 589 active clinical trials seeking participants for Cancer research studies.
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
Recruiting
To learn about the safety and effects of a drug called REGN5678 when it is given to patients with high-risk prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
12/21/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer, Radical Prostatectomy
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: Texas Oncology - Memorial City, Houston, Texas
Conditions: Breast Cancer
Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study
Recruiting
One of the strongest risk factors for cancer in children and adolescents is being born with a congenital anomaly. In fact, data from registry linkage studies imply that 10-15% of childhood cancer risk could be attributable to having a congenital anomaly. As an estimated 10 million children worldwide are born with a congenital anomaly per year, the public health implications of identifying why some of these children develop cancer are thus substantial. While these studies have been informative, r... Read More
Gender:
All
Ages:
0 years and above
Trial Updated:
12/12/2023
Locations: Baylor College of Medicine/ Dan L Duncan Comprehensive Cancer Center, Houston, Texas
Conditions: Congenital Anomaly, Pediatric Cancer
Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer
Recruiting
This is a multicentrer, randomized Bayesian Phase II trial for patients with early stage (T1N0) glottic squamous cell carcinoma treated with radical radiotherapy. The primary objective is to assess the non-inferiority of local control achieved with vocal-cord only radiotherapy (VC-RT) compared to complete larynx radiotherapy (CL-RT) in T1N0 glottic laryngeal squamous cell cancer, measured at 2-years after treatment. Secondary outcomes include overall survival, as well as voice impairment, dyspha... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/11/2023
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Cancer Neck, Larynx Cancer, Glottis Tumor
Childhood Cancer Survivor Study
Recruiting
The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer and its associated therapies. A retrospective cohort study will be conducted through a multi-institutional collaboration, which will involve the identification and active follow-up of a cohort of approximately 50,000 survivors of cancer, diagnosed before 21 years of age, between 1970 and 1999 and 10,000 sibling controls. This project will study children and young adults exposed to specific therapeutic mod... Read More
Gender:
All
Ages:
All
Trial Updated:
12/11/2023
Locations: M.D. Anderson Cancer Center, Houston, Texas +1 locations
Conditions: Cancer
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
Recruiting
To learn if giving immune checkpoint therapy (such as atezolizumab) and bevacizumab to patients who have HCC and are receiving DAAs may help to control HCC and hepatitis C.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/07/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Liver Cancer
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors
Recruiting
Phase I Dose Finding Study for GQ1001 in Patients with HER2-Positive Advanced Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
12/03/2023
Locations: M.D. Anderson Cancer Center, Houston, Texas
Conditions: HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor
TH1902 in Patients With Advanced Solid Tumors
Recruiting
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard chemotherapy, surgery, radiation therapy, and for which no known effective therapies exist. Part 2 (expansion): selected patient populations with recurrent advanced TNBC, HR+ breast cancer, epithelial ovarian cancer, endometrial cancer, cutaneous melanoma, thyroid cancer, SCLC, p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy
Recruiting
The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual at decreasing delays starting guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial aims to answer are: Does ENDURE decrease delays starting PORT relative to treatment as usual? Does ENDURE decrease racial disparities in delays starting PORT relative to treatment as usual What are the me... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oral Cavity Cancer, Larynx Cancer
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
Recruiting
It's propose this pilot phase 2 study to explore the combination therapy of futibatinib with pembrolizumab in patients with metastatic microsatellite stable (MSS) endometrial carcinoma to provide a well-tolerated regimen for durable responses.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Recruiting
This is a multi-center, open-label, phase Ib/II study of APG-2575 as a single agent in patients with advanced solid tumors or in combination with anti-cancer agents such as CDK 4/6 inhibitor palbociclib in patients with ER+/HER2- metastatic breast cancer (mBC) who have progressed or relapsed after first line therapy
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
11/27/2023
Locations: MD Anderson, Houston, Texas
Conditions: Breast Cancer, Solid Tumor, Adult
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Recruiting
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell